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PECAM-1 (CD31) is a member of the immunoglobin (Ig) superfamily of cell adhesion molecules whose expression is
restricted to hematopoietic and vascular cells. PECAM-1 can recruit adapter and signaling molecules via its immunore-
ceptor tyrosine activation motif (ITAM), suggesting that PECAM-1 plays a role in signal transduction pathways. To study
the involvement of PECAM-1 in signaling cascades in vivo, we used the major histocompatibility (MHC) I gene promoter
o target ectopic PECAM-1 expression in transgenic mice. We noted an attenuation of mammary gland development at early
tages of virgin ductal branching morphogenesis. STAT5a, a modulator of milk protein gene expression during lactation, was
ocalized to the nuclei of ductal epithelial cells of 6-week-old virgin PECAM-1 transgenics, but not in control mice. This
orrelated with decreases in ductal epithelial cell proliferation and induction of p21, an inhibitor of cell cycle progression.
sing in vitro model systems we demonstrated PECAM-1/STAT5a association and found that residue Y701 in PECAM-1’s
ytoplasmic tail is important for PECAM-1/STAT5 association and that PECAM-1 modulates increases in STAT5a tyrosine
hosphorylation levels. We suggest that by serving as a scaffolding, PECAM-1 can bring substrates (STAT5a) and enzymes
a kinase) into close proximity, thereby modulating phosphorylation levels of selected proteins, as previously noted for
b-catenin. © 2001 Academic Press
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Platelet-endothelial cell adhesion molecule (PECAM)-1 is
a 130-kDa glycoprotein belonging to the immunoglobin (Ig)
superfamily of cell adhesion molecules. In contrast with
other Ig-family members, PECAM-1 has a relatively long
(118 amino acids) cytoplasmic tail, encoded by seven sepa-
rate exons (Kirschbaum et al., 1994). An immunoreceptor
yrosine-based activation motif (ITAM) domain was re-
ently identified in PECAM-1’s cytoplasmic tail, encoded
y exons 12, 13, and 14 (Lu et al., 1997). An increasing body
f evidence suggests that phosphorylation of the two ITAM
omain tyrosine residues, 663 and 686, is required for
ownstream signaling events observed following PECAM-1
ngagement. The cytoplasmic tail of PECAM-1 contains no
1 Present address: InSight Ltd., P.O. Box 2128, Rabin Science
Park, Rehovot, Israel.
2 To whom correspondence should be addressed. Fax: (203) 785-
303. E-mail: joseph.madri@yale.edu.
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All rights of reproduction in any form reserved.ntrinsic kinase or phosphatase activity, and signaling
vents are therefore thought to occur by the recruitment of
H-2-containing adapter molecules. These include SH-2-
ontaining protein-tyrosine phosphatase (SHP)-1 (Hua et
l., 1998) and SHP-2 (Jackson et al., 1997; Sagawa et al.,
997), SHIP, phospholipase C-g (Pumphrey et al., 1999), and
hosphoinositide 3-kinase (PI3K) (Pellegatta et al., 1998).
PECAM-1 may also associate with adapter or signaling
olecules in an ITAM-independent manner, as was re-
ently shown for b-catenin (Ilan et al., 1999) and g-catenin
(Ilan et al., 2000). PECAM-1 tyrosine phosphorylation has
been observed following biochemical or mechanical stimu-
lation in essentially all PECAM-1-expressing cells (e.g.,
platelets, monocytes, neutrophils, selected T cells, and
endothelial cells). Functionally, PECAM-1 tyrosine phos-
phorylation has been shown to play a role in endothelial
cell migration (Schimmenti et al., 1992; Lu et al., 1996; Kim
et al., 1998) and in mechanosensing (Masuda et al., 1997;
Osawa et al., 1997). Furthermore, changes in PECAM-1
tyrosine phosphorylation levels have been documented
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220 Ilan et al.during mouse conceptus development (Pinter et al., 1997)
and under conditions of hyperglycemia (Pinter et al., 1999),
suggesting that PECAM-1 tyrosine phosphorylation levels
may be important and functional in in vivo settings.
Recently, we reported that PECAM-1 expression in
SW480 colon carcinoma cells resulted in recruitment of
b-catenin into cell–cell junctions, preventing its nuclear
localization (Ilan et al., 1999). Moreover, PECAM-1 overex-
pression in hemangioma-derived EOMA cells resulted in a
decrease in b-catenin tyrosine phosphorylation levels (Ilan
et al., 1999). This is likely to be mediated by PECAM-1-
bound SHP-2, suggesting that PECAM-1 can serve as a
scaffold and bring into close proximity an enzyme and its
substrate, thus actively mediating the phosphorylation lev-
els of selected adapter proteins.
Nevertheless, in vivo demonstration of PECAM-1’s po-
ential function in signaling events has not yet been re-
orted. To further study PECAM-1 functions in vivo, we
sed the major histocompatibility (MHC) class I gene
romoter to drive ectopic PECAM-1 expression in trans-
enic mice. The MHC I gene is ubiquitously expressed and
ts promoter has been studied in detail (Weiss et al., 1983;
imura et al., 1986; Johnson and Pober, 1990; Katoh et al.,
990). Moreover, the MHC I promoter was successfully
sed to direct human cDNA expression in transgenic mice
nd pigs (Fodor et al., 1994). Here we provide evidence that
ctopic expression of PECAM-1 significantly attenuated
ammary gland development. This phenotype appeared
arly in ductal branching morphogenesis and involved a
ecrease in epithelial cell proliferation. Interestingly,
TAT5a was noted to be localized to the nucleus of virgin
uctal epithelial cells in PECAM-1 transgenics, suggesting
n increase in its tyrosine phosphorylation levels. We
onfirmed the involvement of PECAM-1 in regulating
TAT5a phosphorylation levels by establishing in vitro
odel systems and demonstrated PECAM-1/STAT associa-
ions in 293 cells, mammary epithelial cells, and endothe-
ial cells. Thus, we provide for the first time in vivo
vidence for the intimate involvement of PECAM-1 in
elected signaling cascades.
MATERIALS AND METHODS
Animals
Mice used in this study were of B6C3 strain. Transgenic mice
were generated by microinjection of a 0.5-kbp MHC I promoter
region fused to the human PECAM-1 cDNA (Fig. 1A) (Fodor et al.,
1994; Kim et al., 1998) to fertilized mouse eggs according to
tandard protocols (Hogan et al., 1994). Positive founder mice were
identified by Southern blot analysis of genomic DNA extracted
from tail biopsy (Fig. 1B). The same DNA construct that was used
for generating the transgenic strains was used as a probe after
random priming labeling (Boehringer Mannheim, Indianapolis, IN).
Southern blot-positive mice were always studied in comparison
with their nontransgenic littermates. Mice were maintained at the
Yale animal facility and studies were performed according to
approved protocols.
Copyright © 2001 by Academic Press. All rightCells and Cell Cultures, Gene Constructs, and
Transfections
Human umbilical vein endothelial cells (HUVEC) were obtained
from Jordan Pober (Yale Medical School) and were cultured in
gelatin-coated flasks as described (Ilan et al., 1998). Hemangioen-
dothelioma (EOMA) cells were obtained from Robert Auerbach
(University of Wisconsin, Madison) and were grown in complete
FIG. 1. Ectopic PECAM-1 expression in mammary epithelia re-
sults in attenuation of mammary gland development. (A) Sche-
matic representation of the DNA construct used to generate the
transgenic mice comprised of a murine MHC I promoter (H-2Kb
mMHC I) and the human PECAM-1 cDNA (hPECAM-1 cDNA). (B)
Identification of PECAM-1 transgenic mice. Mice were identified
as transgenic by Southern blot analysis of EcoRI-digested tail DNA,
with a 32P-labeled PECAM-1 probe. (C) Impaired mammary gland
morphology of PECAM-1 transgenics. Mammary tissue was har-
vested from normal (a) or transgenic strains (b–d) at Day 1 of
lactation. Hematoxylin/eosin staining reveals impaired mammary
gland morphology for the No. 5 strain (b) and the No. 23 strain (d)
compared to that of the control (a). In these two transgenic strains
there is a significant decrease in terminal differentiation, as judged
by the size of the alveoli. In contrast, the No. 11 strain (c) displayed
no noticeable morphological impairments at this stage of mam-
mary gland development and differentiation. Scale bar 5 100 m.Dulbecco‘s modified Eagle’s medium (DMEM) supplemented with
s of reproduction in any form reserved.
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221PECAM-1/STAT Interactions10% fetal bovine serum (FBS) and antibiotics as described (Obeso et
al., 1990; Ilan et al., 1999).
293T cells were purchased from the ATCC (Rockville, MD) and
ere grown in DMEM supplemented with 10% FBS. Scp2 cells, a
ouse mammary epithelial cell line, were kindly provided by Mina
issell (University of California, Berkeley) and were maintained in
MEM/F12 medium (1:1) supplemented with 2% FBS, 50 mg/ml
gentamicin, and insulin (5 mg/ml).
HEC 293 cells stably expressing PECAM-1 and vector-only (Vo)
ontrol cells were previously described (Ilan et al., 2000). Wild type
nd point-mutated PECAM-1 gene constructs were described else-
here (Lu et al., 1996; Kim et al., 1998). STAT5a and Lck cDNAs
ere kindly provided by Xin-Yuan Fu (Yale University, New Haven
T) (Welte et al., 1999).
DNA (10 mg) was transfected into subconfluent cells with
ipofectAmine reagent (Gibco BRL, Gaithersburg, MD) for 24 h.
ells were stimulated with complete growth medium for 30 min
efore harvesting. Scp2 cells were first stimulated with prolactin (3
mg/ml; Sigma, St. Louis, MO) for 10 min before the addition of
growth medium.
Cell Lysate Preparation, Immunoprecipitation, and
Protein Blotting
Cell cultures were pretreated with 1 mM orthovanadate for 15
min at 37°C, washed twice with ice-cold PBS containing 1 mM
orthovanadate, and scraped into lysis buffer [50 mM Tris, pH 7.4,
150 mM NaCl, 1% NP-40, 10% glycerol, 1 mM orthovanadate, 1
mM PMSF, and a cocktail of proteinase inhibitors (Boehringer
Mannheim, Mannheim, Germany)]. Total cellular protein concen-
tration was determined by the BCA assay (Pierce, Rockford, IL),
according to the manufacturer’s instructions. A 20-mg sample of
cellular protein was fractionated on SDS–polyacrylamide gels and
protein immunoblotting was performed as described (Ilan et al.,
1998). For immunoprecipitation, 100 mg of cellular protein was
brought to volume of 1.0 ml in buffer containing 50 mM Tris, pH
7.5, 150 mM NaCl, 5 mM EDTA, and 0.5% NP-40, preabsorbed
with normal rabbit serum followed by protein A/G-Sepharose
(Santa Cruz Biotechnology, Santa Cruz, CA) precipitation. The
cleared supernate was incubated with the appropriate antibody for
2 h on ice followed by protein A/G-Sepharose immunoprecipita-
tion. Beads were washed three times with the same buffer supple-
mented with 400 mM NaCl (final concentration) and 5% sucrose
and once with the same buffer without sucrose and reduced salt
concentration (50 mM NaCl). Sample buffer was then added and
after boiling samples were subjected to gel electrophoresis and
immunodetection as described. Immunoprecipitation with mono-
clonal antibodies directed against phosphotyrosine (clone 4G10)
was performed according to the manufacturer’s instructions (Up-
state Biotechnology, Lake Placid, NY).
Histology, Immunoperoxidase, and Whole-Mount
and Immunofluorescent Staining
Abdominal and thoracic mammary tissues were harvested from
virgin, midpregnant, or 1-day postpartum animals, fixed with 4%
paraformaldehyde overnight, dehydrated through graded ethanol,
cleared in xylenes, and embedded in paraffin. Five-micron sections
were stained with hematoxylin/eosin or subjected to immuno-
staining, as follows: deparaffinized sections were treated with 0.5%
H O for 10 min, washed, and treated with 0.1% trypsin for 20 min2 2
t 37°C. Sections were than exposed to 2 N HCl for 1 h at 37°C, m
Copyright © 2001 by Academic Press. All rightuenched twice with 0.1 M borate buffer, pH 8.5 (5 minutes each),
ashed and treated with 0.2% Triton-X in PBS for 30 min. Washed
ections were blocked with 10% normal goat/donkey serum for 1 h
nd incubated with the appropriate primary antibody overnight at
°C. HRP-conjugated secondary antibodies (Jackson Immuno-
esearch Laboratories, West Grove, PA) were than applied and
ections were finally stained with a DAB kit according to the
anufacturer’s instructions (Vector Labs, Burlingame, CA), coun-
erstained with hematoxylin, mounted and coverslipped. When
taining with a mouse monoclonal antibodies, a mouse on mouse
M.O.M.) kit was used according to the manufacturer’s instructions
Vector Labs).
For whole-mount staining, harvested mammary tissue was
pread onto glass slides and fixed in acetic acid/ethanol (25% acetic
cid/75% ethanol) for 1 h, dehydrated through graded ethanol, and
efatted in acetone overnight. Slides were then hydrated and
tained with carmalum (Sigma) overnight, dehydrated, and
estained in graded ethanol. Sections were incubated in toluene,
ounted, and coverslipped. All steps were performed at room
emperature. Immunofluorescent staining of cells plated on glass
overslips was performed as previously described (Ilan et al., 1998,
999).
Antibodies and Reagents
The following antibodies were purchased from Santa Cruz Bio-
technology: anti-STAT5a (L-20), anti-STAT1 (E-23), anti-STAT3
(C-20), anti-Lck (3A5), anti-phospho ERK (E-4), anti-p21 (H-164),
anti-phosphotyrosine (PY99), anti-human (C-20), and anti-mouse
(M-20) PECAM-1. Other monoclonal antibodies included anti-
STAT3 (Transduction Laboratories, Lexington, KY), anti-phospho-
STAT5 (Upstate Biotechnology), and anti-BrdU-HRP conjugated
(Boehringer Mannheim). Rabbit polyclonal antibodies to mouse
b-casein were kindly provided by Itamar Barash (Volcani Institute,
Bet Dagan, Israel). Rabbit polyclonal antibodies to human (booboo)
and mouse (sleet) PECAM-1 were previously described (Lu et al.,
1996; Pinter et al., 1999).
BrdU was purchased from Amersham (RPN 201; Amersham,
rlington Heights, IL) and was injected i.p. at 0.01 ml/g. Mice were
erminated 2 h later, and mammary tissues were harvested and
mmunostained as described.
All experiments were repeated at least twice with similar
esults. In vivo experiments were repeated at least three times.
ata were statistically analyzed by the two-sample t test assuming
qual variances.
RESULTS
Impaired Alveoli Morphogenesis in PECAM-1
Transgenic Mice
Evidence to date suggests that PECAM-1 can associate
with several adapter proteins in vitro, suggesting that
PECAM-1 may function as a signaling molecule, in addition
to its adhesion function. To further elucidate PECAM-1’s
potential signaling functions in vivo, we established a
transgenic mouse model in which PECAM-1 was ectopi-
cally expressed. The major histocompatibility complex
(MHC) class I gene is ubiquitously expressed on most
somatic cells. Thus, the murine MHC I gene H2Kb pro-oter was used to control the expression of the human
s of reproduction in any form reserved.
weeks (a), and further ductal branching at 3 months (c) of age. The
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Copyright © 2001 by Academic Press. All rightPECAM-1 cDNA (Fig. 1A) and to confer PECAM-1’s expres-
sion in both vascular and nonvascular cells (Fodor et al.,
1994). Three founder mice, carrying the human gene at
different levels, were identified in a Southern blot analysis
(Fig. 1B). PECAM-1 transgenic mice produced viable litters,
leading us to examine tissues that developed postnatally.
One such tissue is the mammary gland, which develops in
the adult female at puberty and during pregnancy and
lactation. Morphological examination of transgenic mouse
mammary sections made after 1 day of lactation revealed a
significant decrease in alveoli development (Fig. 1C). In the
control mice, the mammary fat pad is filled with well-
developed alveoli and milk components are visible within
the alveolar lumen (Fig. 1Ca). In contrast, in two out of
three of our PECAM-1 transgenic strains (Nos. 5 and 23),
the alveoli are much less developed (Figs. 1Cb and 1Cd),
resulting in an increased mammary-free fat pad, and
matched mammary gland morphogenesis at Day 16 of
pregnancy (data not shown). A third PECAM-1 transgenic
strain (No. 11) showed normal mammary morphogenesis at
lactation (Fig. 1Cc), but a decrease in ductal branching
morphogenesis at early stages of virgin mammary develop-
ment (see below). The decrease in alveoli development in
PECAM-1 transgenic strains Nos. 5 and 23 was accompa-
nied by a decrease in milk protein gene expression as judged
by b-casein immunostaining (data not shown). However,
newborns survived and showed no obvious decrease in
growth rates.
Impaired Mammary Ductal Branching
Morphogenesis in Virgin PECAM-1 Transgenics
Having demonstrated a phenotype for PECAM-1 trans-
genic mice, we were interested in characterizing when in
development the impaired mammary gland phenotype ap-
pears. Whole-mount staining of 6-week- or 3 month-old
virgin mammary gland was performed (Fig. 2). A decrease in
ductal branching and lateral bud formation was noted in
6-week-old PECAM-1 transgenic mice (No. 5, Fig. 2A, upper
panel). This decrease was even more pronounced in
3-month-old virgin transgenics Nos. 5 and 11 (Fig. 2A,
bottom panel), and is best demonstrated at higher magnifi-
cations (Fig. 2B). Thus, in 3-month-old virgin control mice,
the mammary duct system grew out to the edges of the fat
pad (Fig. 2Aa) and subsequently started to develop lateral
buds (Figs. 2Ba and 2Bb) (Robinson et al., 1998), which will
transgenic strains Nos. 5 and 11 both show a basic duct system at
6-week-old (b), and 3-month-old (d and e) virgin animals. However,
a marked reduction in ductal branching (b–e) is noted. (B) A higher
magnification of the 3-month-old whole-mount mammary gland
staining. Note the branched ductal structures of the control,
nontransgenic, mammary gland (a and b), compared to the basic,
nondeveloped, and nonbranched ductal system in PECAM-1 trans-FIG. 2. Ectopic expression of PECAM-1 in mammary epithelia
results in abnormal mammary gland ductal branching morphogen-
esis. (A) Whole-mount staining of 6-week- and 3-month-old con-
trol, nontransgenic (control), and transgenic mouse mammary
glands. Harvested glands were spread onto glass slides, fixed and
stained with carmalum overnight. Staining showed normal devel-
opment of control tissue with well-branched ductal trees at 6genic strains Nos. 5 (c and d) and 11 (e and f). Scale bar 5 200 m.
s of reproduction in any form reserved.
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223PECAM-1/STAT Interactionsfurther develop into alveoli during pregnancy and lactation.
In contrast, PECAM-1 transgenic mice failed to fully ex-
pand the mammary ductal system out to the fat pad borders
at 6 weeks (Fig. 2Ab), and even at 3 months of age (Figs.
2Ad, 2Ae; 2Bc–2Bf) in virgin animals. Moreover, the basic
duct structures were significantly less branched in
PECAM-1 transgenic strains Nos. 5 and 11 (Figs. 2Bc–2Bf),
suggesting that all three transgenic strains exhibit mam-
mary defects. This observation may imply that the lack of
alveoli development and function during early lactation
(Fig. 1B) is a consequence of much earlier (Fig. 2) events.
The normal appearance of strain No. 11 during early lacta-
tion (Fig. 1Cc) may suggest that this particular strain was
able to overcome and compensate for the early defects,
whereas strains Nos. 5 and 23 could not. Moreover, such a
scenario would suggest a significant PECAM-1 expression
during early stages of mammary ductal morphogenesis.
Immunoperoxidase staining of mammary sections of
6-week-old females confirmed PECAM-1 expression in the
transgenic mammary glands. PECAM-1 was noted to be
expressed in the ductal epithelial cells in all three trans-
genic strains (Figs. 3B–3D), and to localize to areas of
cell–cell borders, as would be expected for a cell adhesion
FIG. 3. PECAM-1 expression in control, nontransgenic, and trans-
genic murine mammary glands at 6 weeks of age. Sections of
control (A) and transgenic [B (No. 5), C (No. 23), D (No. 11)]
6-week-old mammary tissues were immunostained for PECAM-1
using the peroxidase system with a DAB substrate. The sections
were counterstained with hematoxylin. PECAM-1 is present in the
epithelial cells surrounding the lumen of the ductal structures in
the transgenic sections and also localizes to cell-to-cell borders.
This staining is absent in the control tissue. The positive staining
confirms the presence of PECAM-1 in mammary epithelial cells
during early stages of development. Scale bar 5 50 m.molecule. A higher expression level was noticed in trans- c
Copyright © 2001 by Academic Press. All rightenic strain No. 5 (Fig. 3B). Moreover, Northern blot anal-
sis revealed a higher PECAM-1 expression in the virgin
ammary gland than that during lactation (data not
hown), further supporting the concept that the decrease in
lveoli development is the result of a decreased ductal
ranching early in mammary gland development.
PECAM-1 Transgenics Exhibit STAT5a Nuclear
Localization and a Decrease in Ductal Epithelial
Cell Proliferation
Before puberty, the mammary ducts elongate and migrate
into the mammary fat pad at a rate that is in pace with the
overall growth of the animal (Hennighausen and Robinson,
1998). Accelerated ductal extension and branching com-
mences with the start of puberty at about 4 weeks of age
and involves a wave of cell proliferation. Thus, the decrease
in ductal arborization seen in PECAM-1 transgenics may be
the result of changes in cell proliferation. To assess this we
performed BrdU incorporation followed by immunostaining
(Fig. 4). In the control sections, BrdU-positive cells were
frequently detected and mainly localized to terminal end
bud (TEB) areas (Fig. 4Aa). In contrast, a significant decrease
in the overall BrdU incorporation and especially in TEB
areas, was noted in the two PECAM-1 transgenic strains
tested, Nos. 5 (Fig. 4Ac) and 23 (Fig. 4B). A twofold decrease
in BrdU-positive cells was calculated after counting 10
random fields in three independent experiments (Fig. 4B), a
statistically significant difference. The decrease in BrdU
incorporation was specific to the mammary epithelium, in
that no change in BrdU immunoreactivity was noted in the
adjacent lymph nodes (Figs. 4Ab and 4Ad). Thus, one
possible explanation for the observed decrease in ductal
morphogenesis is a decrease in TEB formation and/or pro-
liferation.
To gain a molecular insight into this unexpected
PECAM-1 effect, we stained 6-week-old virgin mammary
sections with anti-STAT5a antibodies. STAT5a is known to
play a key role in mammary epithelial cell differentiation
during pregnancy and milk protein gene induction at lacta-
tion in response to a precise hormonal combination.
STAT5a expression levels remain largely unchanged
throughout mammary development (Liu et al., 1996). How-
ver, a robust increase in STAT5a tyrosine phosphorylation
s observed during pregnancy and lactation (Liu et al., 1996),
ollowed by nuclear translocation (Kazansky et al., 1999).
As expected, STAT5a immunoreactivity in virgin, control
mice exhibits a diffuse, cytoplasmic localization (Fig. 5A).
Surprisingly, however, STAT5a was mainly localized to the
nucleus in PECAM-1 transgenics (Fig. 5B), suggesting an
increase in STAT5a tyrosine phosphorylation level. STAT
family members were previously shown to mediate EGF-
induced (Chin et al., 1996) or FGF-induced (Xie et al., 1997)
rowth inhibition of MDA468 and MCF7 breast carcinoma
ells. Activated STAT proteins specifically recognize con-
erved STAT-responsive elements in the promoter of the
yclin-dependent kinase (CDK) inhibitor p21 gene and
s of reproduction in any form reserved.
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Copyright © 2001 by Academic Press. All rightinduces p21 transcription (Chin et al., 1996). Thus, p21
immunostaining was performed (Figs. 5C and 5D). Similar
to the STAT5a staining, p21 appears diffusely distributed in
the cytoplasm of control, nontransgenic, virgin ductal epi-
thelium (Fig. 5C). In contrast, p21 was found to be mainly
localized to the nucleus in PECAM-1 transgenic mammary
sections (Fig. 5D), similar to that of STAT5a localization
(Fig. 5B). Immunostaining with anti-phospho-MAPK anti-
bodies revealed the opposite staining patterns (Figs. 5E and
5F). Phospho-MAPK reactivity was localized to the nucleus
in control, nontransgenic sections (Fig. 5E), but observed to
be cytoplasmic in PECAM-1 transgenic mammary epithe-
lium, with some nuclear localization in the mammary
stroma surrounding the duct structures (Fig. 5F).
Taken together, ectopic expression of PECAM-1 in the
mammary epithelium had a profound effect, altering endog-
enous developmental pathways. Specifically, we suggest
FIG. 5. STAT5a and p21 nuclear localization in transgenic mam-
mary glands ectopically expressing PECAM-1. Mammary tissues
were harvested from 6-week-old control, nontransgenic (A, C, E) or
transgenic (No. 5: B, D, F) mice and paraffin sections were exam-
ined by immunostaining with anti-STAT5a (A and B), anti-p21 (C
and D), and anti-phospho-MAPK (E and F) antibodies using the
peroxidase system with a DAB substrate. Note an increase in
nuclear localization of STAT5a and p21 in the mammary epithe-
lium of PECAM-1 transgenic compared to cytoplasmic localization
in the “controls” sections. In contrast, phosphorylated mitogen-
activated protein kinase (p-MAPK) showed nuclear localization in
control sections (E), but cytoplasmic staining in PECAM-1 trans-FIG. 4. Ectopic expression of PECAM-1 in mammary epithelia
results in decreased ductal epithelial cell proliferation. (A) Six-
week-old transgenic (c and d, No. 5) and control, nontransgenic (a
and b) mice were subjected to in vivo BrdU incorporation. The
animals received an intraperitoneal injection of BrdU 2 h before
termination. Paraffin sections of harvested mammary glands were
examined by immunostaining with anti-BrdU antibody using the
peroxidase system with a DAB substrate and were counterstained
with hematoxylin. Note the decrease in BrdU incorporation in the
transgenic No. 5 mammary tissue (c) compared to that in control
mammary tissue (a). BrdU incorporation in adjacent lymph node
tissues in both control (b) and transgenic (d) mice is similar. Scale
bar 5 200 m. (B) The total number of BrdU-positively labeled cells
ere counted in 15 random fields for both control and transgenic
ections. Each bar represents the average of three separate experi-
ents with transgenic animal and its control, nontransgenic litter
ates, from three different litters. The numbers of positively
abeled cells in the control animals were scaled to represent 100%
f cells proliferating. Both the transgenic mouse strains tested
Nos. 5 and 23) showed a 48.69 and 52.06% decrease in cell
roliferation, respectively. Data were found to be significant to P ,genic ductal epithelium (F). Scale bar 5 50 m.
s of reproduction in any form reserved.
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225PECAM-1/STAT Interactionsthat STAT5a nuclear translocation (presumably resulting
from an increase in its tyrosine phosphorylation levels), at
early stages of ductal morphogenesis may be the cause for
the observed decrease in mammary epithelial cell prolifera-
tion, mediated, at least in part, by p21 induction.
PECAM-1 as a STAT5a Regulator
To better study the potential involvement of PECAM-1
in regulating STAT5a phosphorylation levels we estab-
lished an in vitro model culture system. We transiently
cotransfected STAT5a and Lck gene constructs into 293
cells, which we previously engineered to stably express
PECAM-1 (Fig. 6A, lower panel) (Ilan et al., 2000). It was
previously reported that src (Kazansky et al., 1999; Goi et
al., 2000) and src family members, including Lck (Welte et
al., 1999), can activate STATs. Indeed, STAT5a phosphor-
ylation on tyrosine 694 was detected upon transfection of
STAT5a/Lck genes into the vector-only (Vo) control cells
(Fig. 6A, upper panel). However, a threefold increase in
STAT5a phosphorylation levels was noted upon transfec-
tion of PECAM-1-expressing cells with the same genes,
FIG. 6. An increased STAT5a phosphorylation upon STAT5a/Lck
ene constructs were transiently transfected into 293 cells stably ex
ere analyzed for phospho-STAT5a (upper panel), STAT5a (second
y immunoblot analysis. (B) Immunofluorescence analysis of sim
xpressing cells (c and d) were transiently transfected with STA
hospho-STAT5a (b and d). Note an increase in phospho-STAT5a re
representation of the quantitative analysis of the fluorescence data s
fields in duplicate samples, illustrating a 2.6-fold increase in P-STbased on densitometric analysis and after normalizing the t
Copyright © 2001 by Academic Press. All rightlots to Lck expression (Fig. 6A, third panel). An increase in
TAT5a phosphorylation was further confirmed by trans-
ecting Vo (Figs. 6Ba and 6Bb) or PECAM-1-expressing (Figs.
Bc and 6Bd) cells with STAT5a/Lck genes, followed by
mmunofluorescence staining with anti-STAT5a (a and c)
r anti-phospho-STAT5a (b and d) antibodies. STAT5a was
fficiently and equally expressed in both Vo and PECAM-
-expressing cells (Figs. 6A, second panel; 6Ba; and 6Bc).
owever, an increase in phospho-STAT5a-positive cells
as observed in the presence of PECAM-1 (Fig. 6Bd),
.6-fold over Vo cells, based on counting of 15 random fields
n duplicate samples (Fig. 6C). PECAM-1 lacks any enzy-
atic activity that would directly cause changes in protein
hosphorylation levels. However, we previously reported
hat PECAM-1 may function as a scaffolding molecule
apable of bringing an enzyme (kinase or phosphatase) and
ts substrate into close proximity, thus affecting phosphor-
lation levels (Ilan et al., 1999).
A similar scenario is plausible for a PECAM-1/STAT5a
ssociation. To test this hypothesis cotransfection of
ECAM-1 and STAT5a gene constructs into 293T cells was
erformed and was followed by PECAM-1 immunoprecipi-
nsfection into PECAM-1-expressing 293 cells. (A) STAT5a and Lck
sing PECAM-1 (PEC) or control, vector-only (Vo) cells. Cell lysates
l), Lck (third panel), and PECAM-1 (fourth panel) expression levels
transfection experiment as in (A). Vo (a and b) and PECAM-1-
Lck genes and the cells were stained for STAT5a (a and c) and
ity in the PECAM-1-expressing cells. Scale bar 5 200 m. (C) Graphic
in (B). Phospho-STAT5a-positive cells were counted in 15 random
in the PECAM-1-expressing 293 cells.cotra
pres
pane
ilar
T5a/
activ
hownation (IP). STAT5a was noted to be associated with
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226 Ilan et al.PECAM-1 (Figs. 7A and 7D), consistent with its ability to
directly modulate STAT5a localization in vivo (Fig. 5B) and
hosphorylation levels in vitro (Fig. 6). Cotransfection of
TAT5a with point-mutated PECAM-1 constructs indi-
ated that tyrosine residue 701 (which is not part of the
TAM domain) appears to be a major residue necessary for
ECAM-1/STAT5a interaction (Fig. 7A), although it con-
FIG. 7. PECAM-1/STAT5a association upon transient cotransfec-
tion into 293T cells. (A) 293T cells were cotransfected transiently
with STAT5a and vector-only control DNA (Vo), or with wild type
(WT) or point-mutated at tyrosine 663, 686, and 701 PECAM-1 gene
constructs. Lysate samples were immunoprecipitated with anti-
PECAM-1 antibodies (sc-1505), followed by immunoblotting with
anti-STAT5a (sc-1081). (B) Blots were stripped and reblotted with
anti-PY, illustrating modest contribution of tyrosine residue 701 to
the overall PECAM-1 tyrosine phosphorylation levels. (C) Blots
were stripped and reblotted with anti-PECAM-1 antibodies, illus-
trating the relative expression of PECAM-1 in the various transfec-
tants. (D) Graph of the relative amounts of PECAM-1/STAT5
coprecipitation observed in the various PECAM-1 transfectants.
Note the maximal contribution of the 701 tyrosine residue to
PECAM-1/STAT5a association (A), but its modest contribution to
the overall PECAM-1 phosphorylation levels (B). The lower bands
in (A) and (C) are the IgG heavy-chain molecules used for the IP.ributes less to overall PECAM-1 tyrosine phosphorylation l
Copyright © 2001 by Academic Press. All rightFig. 7B) (Lu et al., 1996, 1997). Densitometric analysis and
ormalizing to the amounts of PECAM-1 pulled down in
he IP (Fig. 7C) revealed a twofold decrease in PECAM-1/
TAT5a association with the 701 mutant (Fig. 7D).
Similarly, we transfected a mouse mammary epithelial
ell line, Scp2 (Desprez et al., 1993), which express STAT5a
ndogenously, with our PECAM-1 gene constructs to con-
rm our finding in a second, and mammary-derived, cell
ype. Lysate samples were analyzed for phospho-STAT5a
Fig. 8A, upper panel), STAT5a (Fig. 8A, middle panel), or
ECAM-1 (Fig. 8A, lower panel) expression levels by immu-
oblotting. A significant increase in STAT5a phosphoryla-
ion levels was noted after transfection of WT PECAM-1
Fig. 8A, upper panel), further confirming our in vitro
bservation with 293 cells (Figs. 6 and 7A) and providing in
itro correlates to our in vivo findings in the mammary
land. This is a significant effect, taking into account
ransfection efficiency of about 15% (Fig. 8B). Moreover,
utation of tyrosine residues 686 and 701 in PECAM-1’s
ytoplasmic tail completely abrogated this induction (Figs.
A and 8C). We therefore suggest that, although the ty-
osine 701 residue may be responsible for the PECAM-1/
TAT5a interaction (Fig. 7), tyrosine 686 may mediate the
ecruitment of a kinase responsible for STAT5a phosphor-
lation.
PECAM-1/STAT Association in Endothelial Cells
Ectopic expression of PECAM-1, in vivo and in vitro,
rovided us with new and interesting information linking
ECAM-1 to previously unknown signaling pathways. To
valuate the existence of similar pathways in the context of
ndothelial cells, IP experiments were performed with
UVEC cell lysates. STAT5 and STAT3 were found to
o-IP with HUVEC PECAM-1 when PECAM-1 antibodies
ere used to immunoprecipitate PECAM-1 (Figs. 9A and
B). To confirm these observations, we performed immu-
oprecipitations with STAT3 and STAT5 antibodies. In
oth instances we observed PECAM-1 to co-IP with these
TAT family members (Figs. 9C and 9D). In additional
tudies, we determined the effects of migration on STAT/
ECAM-1 association. We observed no appreciable changes
n STAT5/PECAM-1 association during HUVEC migration
data not shown). However, we did note a decrease in
TAT3/PECAM-1 association during HUVEC migration
Fig. 9E).
In addition to these studies, we investigated STAT
ECAM-1 association in EOMA cells. IP experiments were
erformed with EOMA cell lysates. Interestingly, only
inimal amounts of STAT3 were found to co-IP with
OMA PECAM-1 (Fig. 10A, upper panel). This observation
uggests that PECAM-1 can associate with different STAT
amily members, depending on the tissue/cell types being
xamined. Interestingly, STAT3 is highly tyrosine phos-
horylated in HUVEC, but not in EOMA cells (Fig. 10A,
ower panel), in agreement with our previous observations,
inking STAT binding to PECAM-1 with an increase of
s of reproduction in any form reserved.
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227PECAM-1/STAT InteractionsSTAT phosphorylation levels (Figs. 6–8). Because EOMA
are tumor-derived cells, we hypothesized that STAT3 may
function to negatively regulate cell growth of primary
HUVEC cultures. We therefore compared STAT3 phosphor-
ylation levels in control, confluent (C), and migrating (M)
cells (Fig. 10B, lower panel). Indeed, a twofold decrease in
STAT3 phosphorylation levels was noted upon cell migra-
FIG. 8. Increased STAT5a tyrosine phosphorylation levels upon
PECAM-1 expression in Scp2 cells is mediated by PECAM-1’s
tyrosine residues 686 and 701. (A) Lysate samples of Scp2 cells
transfected with vector-only (Vo), wild type (WT), or point mutated
PECAM-1 gene constructs (PECAM-1, lower panel) were analyzed
by SDS–PAGE followed by immunoblotting with anti-phospho-
STAT5a (P-STAT5, upper panel), anti-STAT5a (STAT5, second
panel), and anti-PECAM-1 (third panel) antibodies. Note a robust
increase in STAT5a tyrosine phosphorylation in the presence of
wild type PECAM-1, whereas mutation of tyrosine 686 and 701
completely abrogated this increase. 293 vector-only (Vo) control
cells, or 293 cells stably expressing PECAM-1 (Fig. 7) were cotrans-
fected with STAT5a and Lck gene constructs and were included as
a positive control for the phospho-STAT5a antibodies. (B) Immu-
nofluorescence staining of Scp2 cells transfected with PECAM-1,
illustrating the fraction of cells expressing PECAM-1 (as deter-
mined using anti-PECAM-1) (a) and the total number of cells in the
microscopic field as determined by DAPI labeling (b). Scale bar 5
100 m. Note the significant increase in STAT5a phosphorylation
evels (A), in spite of the relatively low (;15%) transfection
fficiency. (C) Quantitation of the fold increase in STAT5a tyrosine
hosphorylation following expression of wild type and the site-
utated PECAM-1 constructs shown in (A).tion (Fig. 10B, first panel), a situation that also induces cell
Copyright © 2001 by Academic Press. All rightroliferation, while STAT3 expression levels were similar
Fig. 10B, third panel).
Thus, we confirmed the concept that PECAM-1 may
unction as a scaffold, bringing particular enzymes and
ubstrates to a close proximity and thereby modulating the
hosphorylation levels of selected proteins. By doing so,
ECAM-1 may participate in the regulation of signaling
ascades.
DISCUSSION
Transgenic mouse technology is a powerful tool, widely
used for basic and biotechnological studies. By using tissue-
specific promoters, one can direct a gene of interest to a
specific tissue or cell type. Milk protein gene promoters are
extensively used to direct a variety of genes to the mam-
FIG. 9. PECAM-1/STAT associations in endothelial cells. Lysates
of HUVEC cell cultures were immunoprecipitated with anti-
PECAM-1 and the resultant precipitates (IP) were analyzed for
STAT5a and PECAM-1 (A) and STAT3 and PECAM-1 (B). To
confirm these interactions, lysates of HUVEC cell cultures were
immunoprecipitated with anti-STAT5a (C) and anti-STAT3 (D)
and the resultant precipitates (IP) were analyzed for PECAM-1.
Lysates of confluent (C) and migrating (M) HUVEC cell cultures
were immunoprecipitated with anti-PECAM-1 and the resultant
precipitates (IP) were analyzed for STAT3 and PECAM-1 (E). These
results were typical of lysates of five independent HUVEC isolates.
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228 Ilan et al.mary gland, enabling basic understanding of this complex
tissue. Most of these promoters, however, are mainly ex-
pressed at gestation and during lactation and, therefore, the
early stages of virgin mammary development are most often
not affected. Driven by the MHC I promoter, PECAM-1
expression was detected in different mouse tissues such as
lung, kidney, and skin (data not shown), with no obvious
phenotype. PECAM-1 expression in the mammary gland,
however, significantly altered early developmental pro-
grams, leading to a decreased ductal branching and, subse-
quently, alveoli development. Mammary gland develop-
ment is a complex process, involving precise coordination
between steroid and peptide hormones (Hennighausen and
Robinson, 1998), cell–cell and cell–matrix interactions
(Roskelley et al., 1995; Boudreau and Bissell, 1998), growth
factor receptors (Jones et al., 1999), kinases (Chodosh et al.,
2000), and phosphatases (Schaapveld et al., 1997).
Branching morphogenesis determines the tissue pattern
for a variety of organs including the lungs, kidney, salivary,
and mammary glands (Daniel et al., 1989). The mammary
gland is unique in its ductal spacing, leaving extensive areas
for infilling by secretory alveoli during lactation. The
achievement and maintenance of this “open” pattern re-
quires systemic and local regulators. TGF b1 has been
demonstrated to be a major local regulator and inhibitor of
ductal branching, but not alveolar, morphogenesis (Daniel
FIG. 10. PECAM-1/STAT3 associations in endothelial cells. (A)
Lysates of HUVEC (Hu) and EOMA (Eo) cell cultures were immu-
noprecipitated with anti-PECAM-1 and the resultant precipitates
(IP) and cell lysate (Ly) samples were analyzed for STAT3 (upper
panel). PECAM-1/STAT3 interactions were noted to be more
robust in HUVEC than in EOMA cells. Lysates of HUVEC (Hu) and
EOMA (Eo) cell cultures were similarly immunoprecipitated with
anti-phosphotyrosine (P-Y) and the resultant precipitates were
blotted for STAT3 (lower panel). STAT3 phosphorylation levels
were noted to be significantly higher in HUVEC than in EOMA
cells. (B) Lysate samples from control, confluent (C), or migrating
(M) cells were immunoblotted with anti-phospho-STAT3 (first
panel), anti-STAT3 (third panel), and anti-actin (second panel)
antibodies. Note the decrease in STAT3 phosphorylation levels
upon cell migration.et al., 1989; Pierce et al., 1993; Joseph et al., 1999). The o
Copyright © 2001 by Academic Press. All rightmajor finding of our present study is the ability of
PECAM-1 to associate with and regulate the phosphoryla-
tion levels (and thus cellular localization) of STAT5a in
vivo and in vitro in different cell types including endothe-
ial cells. This observation may also help explain the
ossible involvement of PECAM-1 in T-cell-receptor (TCR)
ignaling (Newton-Nash and Newman, 2000). Importantly,
uclear translocation of STAT5a in virgin PECAM-1 trans-
enics (Fig. 5B) correlated with a decrease in branching
orphogenesis (Fig. 2) and ductal epithelial cell prolifera-
ion (Fig. 4).Thus, it is important to maintain STAT5a in its
nphosphorylated state before the onset of pregnancy and
o prevent its nuclear translocation.
In the context of the mammary gland, STAT5a is mainly
onsidered as a differentiation factor, leading to milk pro-
ein gene expression during lactation and in response to
rolactin. However, prolactin (Horseman et al., 1997) and
rolactin receptor (Ormandy et al., 1997; Brisken et al.,
999) knockout (KO) mouse studies indicate that prolactin
lso plays an important role at early stages of ductal
ranching morphogenesis. Specifically, the absence of pro-
actin or its receptor lead to an extended network that is
ompletely devoid of terminal or lateral buds (Horseman et
l., 1997). However, tissue transplantation studies revealed
n indirect role of prolactin for branching morphogenesis
Brisken et al., 1999), based on prolactin’s ability to regulate
he function of other endocrine organs responsible for
roducing mammotrophic factors. STAT5a is not likely to
e involved in these early prolactin-mediated effects, is not
hosphorylated (Liu et al., 1996), and is localized to the
ytoplasm (Fig. 5A). Indeed, STAT5a KO mice exhibit
ormal ductal development (Liu et al., 1997) but fail to
actate, suggesting that STAT5a does not play a role at early
tages of ductal development. As would be expected for a
ifferentiation factor, STAT5a translocation to the nucleus
Fig. 5B) resulted in a twofold decrease in cell proliferation
Fig. 4). This was accompanied by induction and nuclear
ranslocation of p21, an inhibitor of cell cycle progression
Fig. 5D), which was previously shown to be regulated by
ther STAT family members (Mui, 1999) and to inhibit
reast cancer cell proliferation (Xie et al., 1997; Johnson et
l., 1998), suggesting that STAT5a may function similarly.
The observed changes in STAT5a tyrosine phosphoryla-
ion and localization in PECAM-1 transgenics in vivo is
onsistent with our in vitro models, clearly demonstrating
role for PECAM-1 in modulating STAT5a phosphoryla-
ion levels. Moreover, we were able to demonstrate, for the
rst time, PECAM-1’s association with STAT family mem-
ers. 293 cells are widely used as a preferential model
ystem because of their highly efficient expression of trans-
ected genes. Transfection of a STAT5a gene construct into
93 cells stably expressing PECAM-1 resulted in a threefold
ncrease in STAT5a phosphorylation levels (Fig. 6). By
otransfection of STAT5a with wild type or point-mutated
ECAM-1 gene constructs we were able to demonstrate
hysical association of PECAM-1 and STAT5a and, more-
ver, that tyrosine residue 701 of the PECAM-1 cytoplas-
s of reproduction in any form reserved.
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ciation (Fig. 7). Thus, while tyrosine residues 663 and 686
have been shown to comprise PECAM-1’s ITAM domain
(Lu et al., 1997) and to mediate the recruitment of SH-2-
containing adapter and signaling molecules (Jackson et al.,
1997; Cao et al., 1998; Pumphrey et al., 1999), tyrosine 701
may represent an additional functional motif within
PECAM-1’s cytoplasmic tail. Moreover, transfection of
Scp-2 mammary-derived epithelial cell line with PECAM-1
gene constructs provides further relevance to our observa-
tion with 293 cells (Fig. 8) (Roskelly et al., 1994). Although
transfection efficiency was significantly lower than that in
293 cells (Fig. 8B), introducing wild type PECAM-1 into
Scp2 cells significantly induced STAT5a phosphorylation.
In addition, point mutation of tyrosine residues 701, as well
as 686, completely abrogated this increase (Figs. 8A and 8C).
We recently reported (Ilan et al., 1999) that PECAM-1 is
involved in regulating the phosphorylation levels of another
protein, b-catenin. Serving as a scaffolding, PECAM-1 may
serve to bring a substrate (tyrosine-phosphorylated
b-catenin) and an enzyme (protein tyrosine phosphatase,
SHP-2) into close proximity, resulting in a decrease in
b-catenin phosphorylation levels. We suggest a similar
scenario for PECAM-1-mediated increased STAT5a phos-
phorylation. Thus, according to this model, tyrosine 701
would be responsible for maximal STAT5a binding to
PECAM-1 (Fig. 7), whereas tyrosine 686 within the ITAM
domain would mediate the recruitment of a kinase that
elicits the increase in STAT5a tyrosine phosphorylation
(Figs. 8A and 8C). Therefore, mutation of either tyrosine
residue, 701 or 686, will prevent a PECAM-1-mediated
increase in STAT5a phosphorylation, as was observed in
our Scp2 model system (Figs. 8A and 8C). The identity of
this putative kinase is not yet clear, but may well be src, or
src-family member (Lu et al., 1997; Osawa et al., 1997),
insofar as they have been implicated in STAT activation
(Kazansky et al., 1999; Welte et al., 1999; Goi et al., 2000).
Lck expression is restricted to immune cells and therefore
is not likely to function in either epithelial or endothelial
cells. Other possibilities include the nonreceptor tyrosine
kinase Bmx, which is able to phosphorylate STATs 1, 3, and
5 (Saharinen et al., 1997) and is expressed mainly in
endothelial cells, or Jak(s). Studies directed at identifying
such a kinase(s) are currently under way.
Because PECAM-1 expression is restricted to cells of the
hematopoietic and vascular systems, it was of great impor-
tance to verify the existence of similar PECAM-1 func-
tion(s) in the context of endothelial cells. Indeed, PECAM-1
was found to be associated with STAT3 and STAT5 in
HUVEC and EOMA cell cultures (Figs. 9 and 10). Interest-
ingly, STAT3 activation has been implicated in both induc-
tion and inhibition of cell growth, depending on the stimu-
lus and cell type. For example, STAT3 activation was noted
in angiotensin II-induced vascular smooth muscle cell pro-
liferation (Marrero et al., 1997) or IL-3 stimulation of
myeloid 32Dc113 cells (Chaturvedi et al., 1998), the latter
being mediated by v-src. On the other hand, STAT3 was e
Copyright © 2001 by Academic Press. All rightlso involved in IL-6-induced (Narimatsu et al., 1997) or
L-10-induced (O’Farrell et al., 1998) growth arrest, medi-
ted in part by induction of the cell cycle inhibitor p19INK4d.
In endothelial cells, STAT family members have been
hown to be activated by the C5b-9 complement complex
Niculescu et al., 1999), oxidized LDL (Maziere et al., 1999),
integrin-mediated adhesion (Brizzi et al., 1999b), and
thrombopoietin (Brizzi et al., 1999a). Moreover, the major
receptor tyrosine kinases specific for endothelial cells [vas-
cular endothelial growth factor receptors (VEGFR) 1, 2, and
3, and Tie 2 (but not Tie 1)] were able to induce STAT3 and
STAT5 (but not STAT1) phosphorylation upon cotransfec-
tion into 293 cells (Korpelainen et al., 1999). In addition,
VEGFR-1 (Flt1) or Tie-2 when cotransfected with STAT5
were able to induce p21 transcription (Korpelainen et al.,
1999). Thus, given the quiescent nature of a confluent
HUVEC culture and the more proliferative behavior of
hemangioma-derived EOMA cells, we propose that STAT3
activation contributes to HUVEC growth arrest. This was
supported by the observed decrease in STAT3 phosphoryla-
tion upon cell migration (Fig. 10B) conditions that also
involve cell proliferation. Therefore, by binding to and
potentially modulating the phosphorylation levels of
STAT3, PECAM-1 may function to stabilize the endothe-
lium. Thus, the mammary gland phenotype may reflect the
function of endogenous PECAM-1 in vascular endothelial
cells. Experiments examining this possibility are currently
under way.
Although the above-mentioned studies focused on new
and interesting interactions between PECAM-1 and STAT
family members (Fig. 11), we cannot exclude the possible
existence of additional mechanisms involved in the alter-
ation of mammary gland development. We recently re-
ported that PECAM-1 functions not only as a sink for
tyrosine phosphorylated b-catenin, maintaining b-catenin
at cell–cell borders, but also as a modulator of b-catenin
dephosphorylation (Ilan et al., 1999). The Wnt pathway has
been implicated as a regulator of the developing mouse
mammary gland (Nusse and Varmus, 1992) and expression
of Wnt-1 gene, which is not normally expressed in the
mammary tissue, contributed to hyperplasia and increased
incidence of tumors (Tsukamoto et al., 1988). Thus, the
presence of PECAM-1 and its ability to bind b-catenin (Ilan
et al., 1999) and g-catenin (Ilan et al., 2000) may interfere
ith the Wnt pathway. Although b-catenin staining ap-
peared unchanged in our PECAM-1 transgenics compared
with that in control mice (data not shown), this possibility
is still valid. The metalloproteinase matrilysin was recently
found to be a target for b-catenin transactivation (Crawford
et al., 1999). Therefore, PECAM-1, either directly or indi-
rectly (by interfering with catenin-regulated-transcription)
may change matrix metalloproteinases (MMP) activity,
which also plays an important role in mammary morpho-
genesis (Sympson et al., 1994; Witty et al., 1995).
Additional work will elucidate further possible functions
f ectopically expressed PECAM-1, shedding light on its
ndogenous function in vascular endothelial cells.
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